LIPO-Liposome Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : LIPO-Liposome

LIPO 0.350

-4.4%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Cacaito who wrote (853)	9/26/1999 12:16:00 PM
From: Donald Gravenor	Read Replies (1) of 900

Doxorubicin is Adriamycin (the commercial name owned by Pharmacia and Upjohn---its just that after being around for 20 years, everyone has had their memory circuits burned into the adria name, rather than the drug compound name). I have prescribed doxil/caelix, and it is indeed very non-cardiotoxic (I gave it to a non-Hodgkins' lymphoma patient with a low cardiac ejection fraction). I don't know whether it is worthwhile to reserrect drugs which were rejected by the FDA---it is an expensive proposition, and generally more clinical trials are necessary (very costly). I have never prescribed the liposomal amphotericin, because of cost (in Canada, we have commisars and bureaucrats who try to resist all spending, and it is us who have to lead the charge to get any particular drug approved onto the hospital formulary). I think that this stock is dead for the forseeable future (say a couple of months), and will bounce around on low volumes. Let me know what you think. (PS I don't own any shares, yet).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next